About ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Sector: N/A
- Symbol: NYSEAMERICAN:IMUC
- CUSIP: 45253610
- Web: imuc.com
- Trailing EPS: ($6.02)
- Return on Assets: -189.02%
- Outstanding Shares: 15,840,000
Frequently Asked Questions for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
What is ImmunoCellular Therapeutics Ltd's stock symbol?
ImmunoCellular Therapeutics Ltd trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IMUC."
How were ImmunoCellular Therapeutics Ltd's earnings last quarter?
ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) released its earnings results on Monday, August, 22nd. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. View ImmunoCellular Therapeutics Ltd's Earnings History.
Are investors shorting ImmunoCellular Therapeutics Ltd?
ImmunoCellular Therapeutics Ltd saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,679,860 shares, a decrease of 0.9% from the October 13th total of 1,694,466 shares. Based on an average trading volume of 2,347,634 shares, the days-to-cover ratio is currently 0.7 days. Approximately 10.6% of the company's stock are short sold.
Who are some of ImmunoCellular Therapeutics Ltd's key competitors?
Some companies that are related to ImmunoCellular Therapeutics Ltd include Metabolix (YTEN), Senestech (SNES), Ampliphi Biosciences Corp (APHB), Ixico Plc (IXI), Roka Bioscience (ROKA), Akers Biosciences (AKR), Rosetta Genomics (ROSG), Celator Pharmaceuticals (CPXX), Cyprotex plc (CRX), Durata Therapeutics (DRTX), GenVec (GNVC), InterMune (ITMN), PAREXEL International (PRXL), Pharmacyclics (PCYC), ShangPharma Corp (SHP) and Synageva Biopharma Corp (GEVA).
Who are ImmunoCellular Therapeutics Ltd's key executives?
ImmunoCellular Therapeutics Ltd's management team includes the folowing people:
- Anthony J. Gringeri Ph.D., President, Chief Executive Officer, Director (Age 62)
- David E. Fractor, Chief Financial Officer (Age 55)
- Rahul Singhvi, Lead Independent Director (Age 50)
- John S. Yu M.D., Director (Age 51)
- Anthony Gregg Lapointe CPA, Independent Director (Age 58)
- Mark A. Schlossberg Esq., Independent Director (Age 56)
- Gary S. Titus, Independent Director (Age 57)
How do I buy ImmunoCellular Therapeutics Ltd stock?
Shares of ImmunoCellular Therapeutics Ltd can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoCellular Therapeutics Ltd's stock price today?
One share of ImmunoCellular Therapeutics Ltd stock can currently be purchased for approximately $0.34.
How big of a company is ImmunoCellular Therapeutics Ltd?
ImmunoCellular Therapeutics Ltd has a market capitalization of $5.35 million.
How can I contact ImmunoCellular Therapeutics Ltd?
ImmunoCellular Therapeutics Ltd's mailing address is 30721 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, CA 91362-7383, United States. The biotechnology company can be reached via phone at +1-818-2642300.
MarketBeat Community Rating for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
Analysts' Ratings History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
(Data available from 11/21/2015 forward)
|8/24/2017||Maxim Group||Reiterated Rating||Hold|
Earnings History and Estimates Chart for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
Earnings History by Quarter for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)
Insider Trades by Quarter for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/30/2015||Andrew Gengos||CEO||Buy||10,000||$0.44||$4,400.00|| |
|2/18/2015||Andrew Gengos||CEO||Buy||41,333||$0.60||$24,799.80|| |
|2/18/2015||Andrew Gengos||CEO||Buy||41,333||$0.60||$24,799.80|| |
|2/18/2015||Anthony Gringeri||VP||Buy||30,000||$0.60||$18,000.00|| |
|2/18/2015||David Fractor||VP||Buy||16,667||$0.60||$10,000.20|| |
|8/21/2014||Anthony Gringeri||VP||Buy||11,000||$0.91||$10,010.00|| |
|8/14/2014||Andrew Gengos||CEO||Buy||10,000||$0.90||$9,000.00|| |
|12/20/2013||Gary Titus||Director||Buy||18,000||$0.78||$14,040.00|| |
|12/18/2013||Andrew Gengos||CEO||Buy||27,000||$0.72||$19,440.00|| |
|10/21/2013||John S Yu||Insider||Sell||267,387||$2.91||$778,096.17|| |
|8/29/2013||James Bender||VP||Sell||14,203||$2.87||$40,762.61|| |
Latest Headlines for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)
ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC) Chart for Tuesday, November, 21, 2017